Prometheus Biosciences Ownership
Prometheus Biosciences owns a total of 47.81 Million outstanding shares. The majority of Prometheus Biosciences outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Prometheus Biosciences to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Prometheus Biosciences. Please pay attention to any change in the institutional holdings of Prometheus Biosciences as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Prometheus Biosciences in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Prometheus Biosciences, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
Prometheus |
Prometheus Stock Ownership Analysis
About 17.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 3.54. Prometheus Biosciences had not issued any dividends in recent years. The entity had 1:100 split on the 1st of November 2013. Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases . Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. Prometheus Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people. To find out more about Prometheus Biosciences contact Mark McKenna at 858 684 1300 or learn more at https://www.prometheusbiosciences.com.Prometheus Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Prometheus Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Prometheus Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Prometheus Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mark McKenna over a year ago Disposition of 178098 shares by Mark McKenna of Prometheus Biosciences subject to Rule 16b-3 | ||
Mark McKenna over a year ago Exercise or conversion by Mark McKenna of 122528 shares of Prometheus Biosciences subject to Rule 16b-3 | ||
Papa Joseph C over a year ago Acquisition by Papa Joseph C of 2278 shares of Prometheus Biosciences subject to Rule 16b-3 | ||
Marshall Keith W over a year ago Exercise or conversion by Marshall Keith W of 10000 shares of Prometheus Biosciences subject to Rule 16b-3 | ||
Mark McKenna over a year ago Exercise or conversion by Mark McKenna of 25000 shares of Prometheus Biosciences subject to Rule 16b-3 | ||
Marshall Keith W over a year ago Exercise or conversion by Marshall Keith W of 10000 shares of Prometheus Biosciences subject to Rule 16b-3 | ||
Mark McKenna over a year ago Exercise or conversion by Mark McKenna of 700 shares of Prometheus Biosciences subject to Rule 16b-3 |
Prometheus Biosciences Outstanding Bonds
Prometheus Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Prometheus Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Prometheus bonds can be classified according to their maturity, which is the date when Prometheus Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
US74348YAV39 Corp BondUS74348YAV39 | View | |
US74348YDX67 Corp BondUS74348YDX67 | View | |
PROSPECT CAP P Corp BondUS74348YEA55 | View | |
US74348TAU60 Corp BondUS74348TAU60 | View | |
US74348TAT97 Corp BondUS74348TAT97 | View | |
US74348TAV44 Corp BondUS74348TAV44 | View | |
PSEC 3437 15 OCT 28 Corp BondUS74348TAW27 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.ZLAB | Zai Lab | |
ASLE | AerSale Corp | |
ATS | AT S Austria |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Other Consideration for investing in Prometheus Stock
If you are still planning to invest in Prometheus Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Prometheus Biosciences' history and understand the potential risks before investing.
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |